IP Library › Granted Patent US 12,251,490
Granted Patent B2
US 12,251,490 · App. 16/337,355 · Granted Mar 18, 2025

Composition of alpha-TCP, silicate and phosphorylated amino acid

Inventors: Philip Procter (Divonne les Bains, FR); Håkan Engqvist (Uppsala, SE); Michael Pujari-Palmer (Uppsala, SE); Gerard Insley (Limerick, IE)
Assignee: BIOMIMETIC INNOVATIONS LIMITED
A61L24/02A61B17/00491A61K6/30A61L24/0031A61L27/12A61L27/52A61B2017/00495A61B2017/005A61L2400/06A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,251,490
App. No.
16/337,355
Granted
Mar 18, 2025
Kind
B2
Abstract

The present invention relates to an aqueous composition comprising an aqueous solution, α-TCP, a silicate compound and a phosphorylated amino acid. The composition has improved mechanical strength and is easily applied and may be used as a tissue adhesive, implant or a filler.

Claims (30)

1. An aqueous composition comprising an aqueous solution, a silicate compound, α-TCP and a phosphorylated amino acid;

wherein the amount of phosphorylated amino acid is 20-50 wt % of the solid content, the combined amount of silicate compound and α-TCP is 10-80 wt % of the solid content, wherein the weight ratio of the silicate compound to α-TCP is 1:1-50; wherein the silicate compound is a mixture of di- and tricalcium silicate; and wherein the composition has a shear strength to bone of at least 1.5 MPa when measured after 24 h of curing at 100% humidity and 37 C.

2. The aqueous composition according to claim 1 wherein the amount of phosphorylated amino acid is 20-30 wt % of the solid content.

3. The aqueous composition according to claim 1 wherein the amount of phosphorylated amino acid is 22-35 wt % of the solid content.

4. The aqueous composition according to claim 1 wherein the weight ratio of the silicate compound to α-TCP is 1:5-15.

5. The aqueous composition according to claim 1 wherein the phosphorylated amino acid is phosphoserine.

6. The aqueous composition according to claim 1 wherein the amount of aqueous solution is 5-20 wt % of the total weight of the composition.

7. The aqueous composition according to claim 1 wherein the composition further comprises a hydrogel.

8. A biological tissue adhesive comprising the composition according to claim 1 .

9. The adhesive according to claim 8 wherein the tissue is a soft tissue.

10. The adhesive according to claim 9 wherein the soft tissue is selected from tendon, ligament, cartilage, fascia, skin, fibrous tissue, muscle, fat, nerve, blood vessel, liver, stomach, intestines, bladder, brain, eyes, uterus, lungs, esophagus, heart, lung, kidney, spleen and glands.

11. The adhesive according to claim 8 wherein the tissue is bone.

12. A bone filler comprising the composition according to claim 1 .

13. A dental implant comprising the composition according to claim 1 .

14. A method of adhering a first tissue to a second surface using the tissue adhesive according to claim 8 comprising:

applying the tissue adhesive according to claim 8 to the first tissue or to the second surface and optionally leave it for a suitable period of time;

bringing the first tissue and the second surface into contact with each other;

optionally applying a pressure on the first tissue and second surface for a suitable period of time; and letting the tissue adhesive cure.

15. The method according to claim 14 wherein the second surface is a second tissue and wherein the first or the second tissue is a soft tissue selected from tendon, ligament, fascia, skin, fibrous tissue, muscle, fat, nerve or blood vessel.

16. The method according to claim 14 wherein the second surface is a ceramic, metal or a polymeric material.

17. The method according to claim 14 wherein the second surface is a synthetic scaffold material selected from synthetic or natural silk, cellulose fibres, or biodegradable fibres selected from PLA, PGA, or PCL containing fibres.

18. The method according to claim 15 wherein both the first and the second tissue is a soft tissue.

19. The method according to claim 14 wherein the steps are performed in vitro.

20. A kit for preparing the composition according to claim 1 comprising at least two containers wherein any one container in the kit can contain any of an aqueous solution, the phosphorylated amino acid, the silicate compound or the α-TCP or a combination thereof, with the provision that both the phosphorylated amino acid and the α-TCP cannot be present in the same container as the aqueous solution; and

wherein the amount of aqueous solution, phosphorylated amino acid, silicate compound and α-TCP in the containers is such that when mixed the composition according to claim 1 is obtained.

21. A syringe comprising at least two compartments wherein any one compartment in the syringe can contain any of an aqueous solution, the phosphorylated amino acid, the silicate compound or the α-TCP or a combination thereof, with the proviso that both the phosphorylated amino acid and the α-TCP cannot be present in the same compartment as the aqueous solution;

wherein the amount of aqueous solution, phosphorylated amino acid, silicate compound and α-TCP in the compartments is such that when mixed the composition according to claim 1 is obtained; and

wherein the syringe further comprises a mixing device configured to mix the components of the at least two compartments.

22. The syringe according to claim 21 wherein any one compartment further comprises an injectable hydrogel.

23. The syringe according to claim 21 wherein any one compartment further comprises a first precursor component for a hydrogel and any second compartment further comprises a complementary precursor component for the first precursor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2021
From: GPBIO LIMITED
To: BIOMIMETIC INNOVATIONS LIMITED
Reel/Frame 056561/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2019
From: PROCTER, PHILIP; ENGQVIST, HAKAN; PUJARI-PALMER, MICHAEL; INSLEY, GERARD
To: GPBIO LTD.
Reel/Frame 049729/0056 →
Priority Claims (1)
SE 1651271-7 · Sep 27, 2016 · national
Continuity (1)
Related Publication 20200038545A1 · Feb 6, 2020
References Cited (38)
US 6533821B1 · Lally · 2003 [cited by applicant]
US 8105086B2 · Asgary · 2012 [cited by applicant]
US 11247941B2 · Hess et al. · 2022 [cited by applicant]
US 11638777B2 · Hess et al. · 2023 [cited by applicant]
US 20050217538A1 · Reinstorf et al. · 2005 [cited by applicant]
US 20090087390A1 · Modi · 2009 [cited by applicant]
US 20100121459A1 · Garigapati et al. · 2010 [cited by applicant]
US 20110277931A1 · Garigapati et al. · 2011 [cited by applicant]
US 20120288446A1 · Garigapati et al. · 2012 [cited by applicant]
US 20130122057A1 · Garigapati et al. · 2013 [cited by applicant]
US 20200030483A1 · Procter · 2020 [cited by applicant]
CN 101014376A · 2007 [cited by applicant]
WO WO2006041365 · 2006 [cited by applicant]
WO WO2016196371 · 2016 [cited by applicant]
WO WO2018060287 · 2018 [cited by applicant]
Office Action issued for CN 201780059294.7 dated Apr. 6, 2021 (English translation) 21 pgs. [cited by applicant]
Correa et al., “α-Tricalcium phosphate cements modified with β-dicalcium silicate and tricalcium aluminate: Physicochemical characterization, in vitro bioactivity and cytotoxicity”, J. Biomedical Materials Research B: A… [cited by applicant]
Dorozhkin, “Calcium orthophosphate-based biocomposites and hybrid biomaterials”, J Mater Sci (2009) 44:2343-2387. [cited by applicant]
International Search report for PCT/EP2017/074551, dated Dec. 13, 2017, 3 pages. [cited by applicant]
Morejon-Alonso et al., “Effects of Silica Addition on the Chemical, Mechanical and Biological Properties of a New α-Tricalcium Phosphate/Tricalcium Silicate Cement”, Materials Research, 2011, 14(4): 475-482. [cited by applicant]
Mostafa et al., “Injectable Bone Cement Based on Calcium Silicate and Calcium Phosphate”, Int. J. Chem. Sci.: 13(1), 2015: 80-96. [cited by applicant]
Motisuke et al., “Apatite bone cement reinforced with calcium silicate fibers”, J. Mater Sci: Mater Med (2014) 25:2357-2363. [cited by applicant]
Schneiders et al., “Effect of modification of hydroxyapatite/collagen composites with sodium citrate, phosphoserine, phosphoserine/RGD-peptide and calcium carbonate on bone remodeling”, Bone 40 (2007): 1048-1059. [cited by applicant]
Office Action mailed Jul. 12, 2023 with respect to U.S. Appl. No. 16/337,350. [cited by applicant]
Coppey, et al., “Early Complications From the Use of Calcium Phosphate Paste in Mandibular Lengthening Surgery. A Retrospective Study” J Oral Maxillofac Surg. 2017;75(6):1274.e1-1274.e10. doi:10.1016/j.joms.2017.01.017. [cited by applicant]
Duan, et al., “Applications of Bioadhesives: A Mini Review”, Frontiers in Bioengineering and Biotechnology, Sep. 2021 Vol. 9:7; 1-12., Seot. 2021, 1-12. [cited by applicant]
Ge, et al., “Review: Recent Advances in Tissue Adhesives for Clinical Medicine”, Polymers, (2020) 12:939 p. 1-22. [cited by applicant]
Hexarmor, “Concrete irritation, burns, and dermatitis”, Retrieved Aug. 26, 2022, from https://www.hexarmor.com/posts/concrete-irritation-burns-and-dermatitis. [cited by applicant]
International Search Report, for PCT/EP2017/074553, dated Dec. 13, 2017, 3 pages. [cited by applicant]
Li, et al., “Ability of Obturation Materials to Improve the Seal of the Root Canal System—a Review”, Acta Biomater. (2014) 10(3): pp. 1050-1063. [cited by applicant]
NPL, search for “phosphoserine” in PubChem; downloaded May 1, 2020. [cited by applicant]
Office Action, issued for U.S. Appl. No. 16/337,350 dated May 7, 2020, 52 pages. [cited by applicant]
Office Action, issued for U.S. Appl. No. 16/337,350 dated Nov. 4, 2020, 14 pages. [cited by applicant]
Office Action, issued for U.S. Appl. No. 16/337,350 dated Jul. 26, 2021, 27 pages. [cited by applicant]
Office Action, issued for U.S. Appl. No. 16/337,350 dated Sep. 10, 2021, 14 pages. [cited by applicant]
Office Action, issued for U.S. Appl. No. 16/337,350 dated Apr. 1, 2022, 16 pages. [cited by applicant]
Office Action, issued for U.S. Appl. No. 16/337,350 dated Nov. 30, 2022, 33 pages. [cited by applicant]
Van Loghem, et al., “Managing intravascular complications following treatment with calcium hydroxylapatite: An expert consensus” J Cosmet Dermatol. 2020;19(11):2845-2858. doi: 10.1111/jocd.13353. [cited by applicant]